Literature DB >> 15235072

Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner.

Dinko E González Trotter1, Ravindra M Manjeshwar, Mohan Doss, Calvin Shaller, Matthew K Robinson, Reeti Tandon, Gregory P Adams, Lee P Adler.   

Abstract

UNLABELLED: Time-dependent PET imaging can be an important tool in the assessment of radiotracer performance in murine models. We have performed a quantitative analysis of PET images of (124)I, acquired on a clinical PET system using a small-animal phantom. We then compared the recovered activity concentrations with the known activity concentration in the phantom spheres. The recovery coefficients found from the phantom data were applied to in vivo (124)I anti-HER2/neu C6.5 diabody PET data and compared with necropsy biodistribution data from the same tumor-bearing immunodeficient mouse.
METHODS: The small-animal phantom consisted of a 4 x 8 cm water-filled acrylic cylinder with hollow spheres filled with water ranging in volume from 0.0625 to 1.0 mL and activity concentration of 27 +/- 2 kBq/mL. The background activity concentrations varied from 0 to 0.05 to 0.10 of the spheres. Data were acquired at 0, 5, and 10 cm from the scanner longitudinal axis. Recovery coefficients were theoretically calculated for spheres of different volume, background-to-target concentrations, and distance from the scanner's longitudinal axis. The theoretic recovery coefficients were applied to the maximum sphere activity concentration measured from the PET images, thus obtaining a recovered activity concentration to be compared with the known activity concentration of the spheres.
RESULTS: The mean recovered activity concentration for the phantom spheres was 25 +/- 2 kBq/mL. The (124)I diabody PET image of a mouse with a tumor xenograft was then analyzed using the techniques described. The tumor percentage injected dose per gram estimated from the murine PET image (4.8 +/- 0.4) compared well with those obtained from necropsy studies (5.1).
CONCLUSION: This study indicates the feasibility of performing quantitative imaging on murine (124)I antibody fragment PET images using a large-bore clinical scanner, which enables high-throughput studies to evaluate the performance of PET tracers in a timely and cost-effective manner by imaging multiple animals simultaneously. Tracers deemed promising by this screening method can then be further evaluated using traditional necropsy studies. Our group is currently conducting time-dependent (124)I diabody PET and necropsy comparative studies with larger numbers of mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15235072

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  14 in total

Review 1.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

2.  Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.

Authors:  Smitha Reddy; Calvin C Shaller; Mohan Doss; Irina Shchaveleva; James D Marks; Jian Q Yu; Matthew K Robinson
Journal:  Clin Cancer Res       Date:  2010-12-21       Impact factor: 12.531

Review 3.  Current and future use of positron emission tomography (PET) in breast cancer.

Authors:  David A Mankoff; William B Eubank
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-04       Impact factor: 2.673

4.  Small-animal imaging using clinical positron emission tomography/computed tomography and super-resolution.

Authors:  Frank P DiFilippo; Sagar Patel; Kewal Asosingh; Serpil C Erzurum
Journal:  Mol Imaging       Date:  2012-06       Impact factor: 4.488

Review 5.  Immuno-positron emission tomography in cancer models.

Authors:  Smitha Reddy; Matthew K Robinson
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

6.  Impact of expression system on the function of the C6.5 diabody PET radiotracer.

Authors:  Joshua Miller; Mohan Doss; Ryan McQuillen; Calvin C Shaller; Berend Tolner; Jian Q Yu; Kerry Chester; Matthew K Robinson
Journal:  Tumour Biol       Date:  2012-03-01

Review 7.  Quantitative imaging of 124I and 86Y with PET.

Authors:  Mark Lubberink; Hans Herzog
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

8.  Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody.

Authors:  Jonathan S Wall; Stephen J Kennel; Mike Paulus; Jens Gregor; Tina Richey; James Avenell; Jeffrey Yap; David Townsend; Deborah T Weiss; Alan Solomon
Journal:  J Nucl Med       Date:  2006-12       Impact factor: 10.057

9.  Comparative positron-emission tomography (PET) imaging and phototherapeutic potential of 124I- labeled methyl- 3-(1'-iodobenzyloxyethyl)pyropheophorbide-a vs the corresponding glucose and galactose conjugates.

Authors:  Suresh K Pandey; Munawwar Sajjad; Yihui Chen; Xiang Zheng; Rutao Yao; Joseph R Missert; Carrie Batt; Hani A Nabi; Allan R Oseroff; Ravindra K Pandey
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

10.  Compared to purpurinimides, the pyropheophorbide containing an iodobenzyl group showed enhanced PDT efficacy and tumor imaging (124I-PET) ability.

Authors:  Suresh K Pandey; Munawwar Sajjad; Yihui Chen; Anupam Pandey; Joseph R Missert; Carrie Batt; Rutao Yao; Hani A Nabi; Allan R Oseroff; Ravindra K Pandey
Journal:  Bioconjug Chem       Date:  2009-02       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.